Pediatric Brain Tumor

Dear Colleagues,

Pediatric brain tumors are the most common solid tumors affecting infants and young children. Among them, high grade gliomas, diffuse intrinsic pontine glioma (DIPG), ependymoma, embryonal tumors including medulloblastoma, and atypical teratoid rhabdoid tumor (ATRT) etc. remain devastating, often refractory to surgical resection and adjuvant radio-chemotherapy, leading to poor patient survival. Advanced research analyses have shown tumor heterogeneity and plasticity, genetic mutations, microenvironment and metabolic alterations, and chromatin remodeling are contributors that challenge current therapeutic strategies which result in unfavorable clinic outcomes.

This special issue will present advanced clinical and research articles and high quality review-papers focusing on the latest advances in the treatment of pediatric malignant brain tumors, which may include targeted therapy and immunotherapy. We request research scientists to submit the results of not only molecular-based but translational investigations of malignant pediatric brain tumors directing for prospective clinical applications. We encourage clinicians to submit their articles describing innovative diagnostic (e.g. liquid biopsy; molecular classification), and therapeutic approaches and protocols with their results.  Surgeons are encouraged to submit their experience of minimally invasive surgery and regional therapy such as convection enhanced delivery, radiation therapy and thermo-ablation in order to contribute to the care of prospective pediatric brain tumors. Comprehensive up-to-date reviews to these topics are also encouraged in order to summarize and understand the current status and future directions.

Prof. Dr. Tadanori Tomita
Dr. Guifa Xi
Prof. Dr. Stewart Goldman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.